Humanization with CD34-positive hematopoietic stem cells in NOG-EXL mice results in improved long-term survival and less severe myeloid cell hyperactivation phenotype relative to NSG-SGM3 mice

NSG-SGM3 and NOG-EXL mice combine severe immunodeficiency with transgenic expression of human myeloid stimulatory cytokines, resulting in marked expansion of myeloid populations upon humanization with CD34+ hematopoietic stem cells (HSCs). Humanized NSG-SGM3 mice typically develop a lethal macrophag...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Veterinary pathology Ročník 61; číslo 4; s. 664
Hlavní autoři: Willis, Elinor, Verrelle, Jillian, Banerjee, Esha, Assenmacher, Charles-Antoine, Tarrant, James C, Skuli, Nicholas, Jacobson, Moriah L, O'Rouke, Donald M, Binder, Zev A, Radaelli, Enrico
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 01.07.2024
Témata:
Animals
Antigens, CD34 - metabolism
Disease Models, Animal
Hematopoietic Stem Cell Transplantation
Hematopoietic Stem Cells - pathology
Humans
Mice
Mice, Transgenic
Myeloid Cells - pathology
Phenotype
NOG-EXL
mouse
humanization
macrophage activation syndrome
hemophagocytic lymphohistiocytosis
mast cell hyperplasia
NSG-SGM3
human hematopoietic stem cells
ISSN:1544-2217, 1544-2217
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:NSG-SGM3 and NOG-EXL mice combine severe immunodeficiency with transgenic expression of human myeloid stimulatory cytokines, resulting in marked expansion of myeloid populations upon humanization with CD34+ hematopoietic stem cells (HSCs). Humanized NSG-SGM3 mice typically develop a lethal macrophage activation syndrome and mast cell hyperplasia that limit their use in long-term studies (e.g., humanization followed by tumor xenotransplantation). It is currently unclear to what extent humanized NOG-EXL mice suffer from the same condition observed in humanized NSG-SGM3 mice. We compared the effects of human CD34+ HSC engraftment in these two strains in an orthotopic patient-derived glioblastoma model. NSG-SGM3 mice humanized in-house were compared to NOG-EXL mice humanized in-house and commercially available humanized NOG-EXL mice. Mice were euthanized at humane or study endpoints, and complete pathological assessments were performed. A semiquantitative multiparametric clinicopathological scoring system was developed to characterize chimeric myeloid cell hyperactivation (MCH) syndrome. NSG-SGM3 mice were euthanized at 16 weeks after humanization because of severe deterioration of clinical conditions. Humanized NOG-EXL mice survived to the study endpoint at 22 weeks after humanization and showed less-severe MCH phenotypes than NSG-SGM3 mice. Major differences included the lack of mast cell expansion and limited tissue/organ involvement in NOG-EXL mice compared to NSG-SGM3 mice. Engraftment of human lymphocytes, assessed by immunohistochemistry, was similar in the two strains. The longer survival and decreased MCH phenotype severity in NOG-EXL mice enabled their use in a tumor xenotransplantation study. The NOG-EXL model is better suited than the NSG-SGM3 model for immuno-oncology studies requiring long-term survival after humanization.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1544-2217
1544-2217
DOI:10.1177/03009858231222216